Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 16/9/2020
SIETES contiene 93091 citas

 
 
 1 a 20 de 1024 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Haugaard JH, Kofoed K, Gislason G, Dreyer L, Egeberg A. Association between drug use and subsequent diagnosis of lupus erythematosus. JAMA Dermatol 2020:2 de septiembre. [Ref.ID 103711]
2. Cita con resumen
Song HJ, Jiang X, Henry L, Nguyen MH, Park H. Proton pump inhibitors and risk of liver cancer and mortality in patients with chronic liver disease: a systematic review and meta-analysis. Eur J Clin Pharmacol 2020;76:851-66. [Ref.ID 103643]
3.Enlace a cita original Cita con resumen
Wang Y-H, Wintzell V, Ludvigsson JF, Svanström H, Pasterenak B. Association between proton pump inhibitor use and risk of fracture in children. JAMA Pediatrics 2020:1. [Ref.ID 103566]
4. Cita con resumen
5. Cita con resumen
Lassalle M, Le Tri L, Bardou M, Biour M, Kirchgesner J, Rouby F, Dumarcet N, Zureik M, Dray-Spira R. Use of proton pump inhibitors in adults in France: a nationwide drug utilization study. Eur J Clin Pharmacol 2020;76:449-57. [Ref.ID 103532]
6. Cita con resumen
Khan MA, Yuan Y, Iqbal U, Kamal S, Khan M, Khan Z, Lee W, Howden CW. No association linking short-term proton pump inhibitor use to dementia: Systematic review and meta-analysis of observational studies. Am J Gastroenterol 2020:2 de enero. [Ref.ID 103525]
7.Enlace a cita original Cita con resumen
Moayyedi P, Eikelboom JW, Bosch J, Connolly SJ, Dyal L, Shestakovska O, Leong D, Anand SS, Störk S, Branch KRH, Bhatt DL, Verhamme PB, O'Donnell M, Maggioni AP, Lonn EM, Piegas LS, Ertl G, Keltai M, Bruns NC, Muehlhofer E, Dagenais GR, Kim JH, Hori M, Steg PG, Hart RG, Diaz R, Alings M, Widimsky P, Avezum A, Probstfield J, Zhu J, Liang Y, Lopez-Jaramillo P, Kakkar AK, Parkhomenko AN, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Vinereanu D, Tonkin AM, Lewis BS, Felix C, Yusoff K, Metsarinne KP, Fox KAA, Yusuf S, COMPASS Investigators. Pantoprazole to prevent gastroduodenal events in patients receiving rivaroxaban and/or aspirin in a randomized, double-blind, placebo-controlled trial. Gastroenterology 2019;157:agosto. [Ref.ID 103177]
8.Enlace a cita original Cita con resumen
Egilman AC, Zhang AD, Wallach JD, Ross JS. Medicare Part D spending on single-enantiomer drugs versus their racemic precursors . Ann Intern Med 2019:13 de agosto. [Ref.ID 103162]
10.Enlace a cita original Cita con resumen
Moore N, Duret S, Grolleau A, Lassalle R, Barbet V, Duong M, Thurin N, Droz-Perroteau C, Gulmez SE. Previous drug exposure in patients hospitalised for acute liver injury: a case-population study in the French National Healthcare Data System. Drug Saf 2019;42:abril. [Ref.ID 103083]
12.Enlace a cita original Cita con resumen
Rodríguez-Martín S, Martín-Merino E, Lerma V, Rodríguez-Miguel A, González O. Incidence of Stevens-Johnson syndrome/toxic epidermal necrolysis among new users of different individual drugs in a European population: a case-population study. Eur J Clin Pharmacol 2019;75:febrero. [Ref.ID 103013]
13.Enlace a cita original Cita con resumen
Ray WA, Chung CP, Murray KT, Smalley WE, Daugherty JR, Dupont WD, Stein M. Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding. JAMA 2018;320:4 de diciembre. [Ref.ID 102867]
14.Enlace a cita original Cita con resumen
Harding BN, Weiss NS, Walker RL, Larson EB, Dublin S. Proton pump inhibitor use and the risk of fractures among an older adult cohort. Pharmacoepidemiol Drug Saf 2018;27:junio. [Ref.ID 102801]
15.Enlace a cita original Cita con resumen
Qato DM, Ozenberger K, Olfson M. Prevalence of prescription medications with depression as a potential adverse effect among adults in the United States. JAMA 2018;319:12 de junio. [Ref.ID 102780]
16. Cita con resumen
Cook D, Guyatt G. Prophylaxis against upper gastrointestinal bleeding in hospitalized patients. N Engl J Med 2018;378:2506-16. [Ref.ID 102735]
17.Enlace a cita original Cita con resumen
Malhotra K, Katsanos AH, Bilal M, Ishfaq MF, Goyal N, Tsivgoulis G. Cerebrovascular outcomes with proton pump inhibitors and thienopyridines. Stroke 2018;49:febrero. [Ref.ID 102619]
18.Enlace a cita original Cita con resumen
Gray SL, Walker RL, Dublin S, Yu O, Aielo Bowles EJ, Anderson ML, Crane PK, Larson EB. Proton pump inhibitor use and dementia risk: prospective population-based study. J Am Geriatr Soc 2018;66:febrero. [Ref.ID 102537]
19. Cita con resumen
Torvinen-Kiskinen S, Tolppanen A-M, Koponen M, Tanskanen A, Tihonen J, Hartikainen S, Taipale H. Proton pump inhibitor use and risk of hip fractures among community-dwelling persons with Alzheimer's disease—a nested case-control study. Aliment Pharmacol Ther 2018;47:1135-42. [Ref.ID 102491]
20. Cita con resumen
Bakhriansyah M, Souverein PC, de Boer A, Klungel OH. Gastrointestinal toxicity among patients taking selective COX-2 inhibitors or conventional NSAIDs, alone or combined with proton pump inhibitors: a case–control study. Pharmacoepidemiol Drug Saf 2017;26:1141-8. [Ref.ID 102084]
Seleccionar todas
 
 1 a 20 de 1024 siguiente >>